SE437832B - Forfarande for framstellning av 3,7-disubstituerade-3-cefem-4-karboxylsyraforeningar - Google Patents

Forfarande for framstellning av 3,7-disubstituerade-3-cefem-4-karboxylsyraforeningar

Info

Publication number
SE437832B
SE437832B SE7702547A SE7702547A SE437832B SE 437832 B SE437832 B SE 437832B SE 7702547 A SE7702547 A SE 7702547A SE 7702547 A SE7702547 A SE 7702547A SE 437832 B SE437832 B SE 437832B
Authority
SE
Sweden
Prior art keywords
hydroxy
cefem
disubstituted
preparing
procedure
Prior art date
Application number
SE7702547A
Other languages
English (en)
Swedish (sv)
Other versions
SE7702547L (sv
Inventor
T Kamiya
K Tanaka
Y Nakai
K Sakane
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9425/76A external-priority patent/GB1575803A/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of SE7702547L publication Critical patent/SE7702547L/
Publication of SE437832B publication Critical patent/SE437832B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7702547A 1976-03-09 1977-03-07 Forfarande for framstellning av 3,7-disubstituerade-3-cefem-4-karboxylsyraforeningar SE437832B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9425/76A GB1575803A (en) 1976-03-09 1976-03-09 3,7 disubstituted 3 cephem 4 carboxylic acid compounds andprocesses for the preparation thereof
GB4114576 1976-10-04

Publications (2)

Publication Number Publication Date
SE7702547L SE7702547L (sv) 1977-09-10
SE437832B true SE437832B (sv) 1985-03-18

Family

ID=26242927

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7702547A SE437832B (sv) 1976-03-09 1977-03-07 Forfarande for framstellning av 3,7-disubstituerade-3-cefem-4-karboxylsyraforeningar
SE8302027A SE454988B (sv) 1976-03-09 1983-04-12 (2 ev. sub. amino -1,3-tiazol-5-yl)-glyoxylsyra derivat till anvendning som mellanprodukt till motsvarande cefalosporinsyror

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8302027A SE454988B (sv) 1976-03-09 1983-04-12 (2 ev. sub. amino -1,3-tiazol-5-yl)-glyoxylsyra derivat till anvendning som mellanprodukt till motsvarande cefalosporinsyror

Country Status (10)

Country Link
US (1) US4560765A (US06168776-20010102-C00028.png)
AR (2) AR218241A1 (US06168776-20010102-C00028.png)
CA (1) CA1218054A (US06168776-20010102-C00028.png)
DE (1) DE2760288A1 (US06168776-20010102-C00028.png)
DK (2) DK168863B1 (US06168776-20010102-C00028.png)
ES (5) ES456625A1 (US06168776-20010102-C00028.png)
HU (2) HU176455B (US06168776-20010102-C00028.png)
IE (1) IE44888B1 (US06168776-20010102-C00028.png)
MX (1) MX4658E (US06168776-20010102-C00028.png)
SE (2) SE437832B (US06168776-20010102-C00028.png)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE55406B1 (en) * 1982-08-07 1990-09-12 Tanabe Seiyaku Co Novel cephalosporin compounds and preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1399086A (en) * 1971-05-14 1975-06-25 Glaxo Lab Ltd Cephalosporin compounds
US4093803A (en) * 1971-05-14 1978-06-06 Glaxo Laboratories Limited 7β-[2-Etherified oximino-2-(thienyl-, furyl- or pyridylacetamido)] cephalosporins
SE417968B (sv) * 1972-10-20 1981-04-27 Fujisawa Pharmaceutical Co Forfarande for framstellning av penamderivat
US4113940A (en) * 1973-03-15 1978-09-12 Fujisawa Pharmaceutical Co., Ltd. 7-amino 2-lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives and processes for preparation thereof
JPS5119765A (en) * 1974-08-09 1976-02-17 Takeda Chemical Industries Ltd Aminochiazoorujudotaino seizoho
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
US4298606A (en) * 1974-12-19 1981-11-03 Takeda Chemical Industries, Ltd. Thiazolylacetamido compounds
DE2715385A1 (de) * 1976-04-14 1977-11-10 Takeda Chemical Industries Ltd Cephalosporinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel

Also Published As

Publication number Publication date
ES476076A1 (es) 1979-05-16
ES456625A1 (es) 1978-07-16
DK168863B1 (da) 1994-06-27
DE2760288A1 (US06168776-20010102-C00028.png) 1985-05-09
ES476075A1 (es) 1979-05-16
AR222010A1 (es) 1981-04-15
DK101477A (da) 1977-09-10
ES467635A1 (es) 1979-09-01
IE44888B1 (en) 1982-05-05
AR218241A1 (es) 1980-05-30
DK139691D0 (da) 1991-07-25
DK139691A (da) 1991-07-25
SE7702547L (sv) 1977-09-10
HU179016B (en) 1982-08-28
US4560765A (en) 1985-12-24
HU176455B (en) 1981-03-28
SE8302027D0 (sv) 1983-04-12
IE44888L (en) 1977-09-09
MX4658E (es) 1982-07-19
SE454988B (sv) 1988-06-13
ES476077A1 (es) 1979-05-16
CA1218054A (en) 1987-02-17
SE8302027L (sv) 1983-04-12

Similar Documents

Publication Publication Date Title
NO820264L (no) Fremgangsmaate for fremstilling av 2-penemforbindelser
ES8401961A1 (es) Procedimiento para la preparacion de nuevas n-(4-indolil-piperidino-alcohil-bencimidazolonas sustituidas.
ES526002A0 (es) Un procedimiento de preparacion de nuevas cefalosporinas
DE3869173D1 (de) Amino 5,6,7,8-tetrahydronaphtho(2,3b)furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
SE8207302D0 (sv) Nya 2-pyrrolidonforeningar och forfarande for framstellning av desamma
ES508343A0 (es) "procedimiento para la preparacion de nuevas pirimido (5,4-d) pirimidinas trisustituidas".
SE8204418D0 (sv) N-imidazolyl-derivat av 1,2,3,4-tetrahydronaftalen, indan och 2-substituerad-1-kroman, och forfarande for deras framstellning
DE3367215D1 (en) Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them
IL61687A (en) (benzothiazole-2-yl-thio)-phenylpropionic acid derivatives,pharmaceutical formulations containing them and a process for their preparation
SE437832B (sv) Forfarande for framstellning av 3,7-disubstituerade-3-cefem-4-karboxylsyraforeningar
YU265482A (en) Process for obtaining cephalosporins substituted in position 3 by a heterocyclic thiomethy group
SE8301785L (sv) Sett att framstella 2-tiofen-ettiksyraderivat och mellanprodukter erforderliga for deras framstellning
DE3173642D1 (en) Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and intermediates for their preparation
AU547599B2 (en) Tricyclic compounds
ES454265A1 (es) Un procedimiento para la obtencion de nuevas cefalosporinas.
SE7905025L (sv) Tereftalsyramonoamidderivat, forfarande for framstellning derav och antiallergiskt medel
GB2001068A (en) Penicillin and cephalosporin preparation
NZ192475A (en) Indanyloxamic derivatives and pharmaceutical compositions
FI882667A (fi) Foerfarande foer framstaellning av antibakteriska vid 7-staellningen substituerade 1-cyklopropyl-6-fluor -1,4-dihydro-4-oxo-1,8-naftyridin-3-karboxylsyror.

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7702547-6

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7702547-6

Format of ref document f/p: F